For people with HIV and fatty liver disease on INSTI drugs, tesamorelin likely reduces liver fat by 4.9% while placebo has almost no effect (0.1% decrease) after a year.

Scientific Claim

Among individuals with HIV and non-alcoholic fatty liver disease on integrase inhibitor therapy, tesamorelin treatment is likely associated with a 4.9% absolute decrease in hepatic fat fraction compared to a 0.1% decrease in placebo after 12 months (p=0.015).

Original Statement

“the tesamorelin treated group saw a 31% relative reduction in HFF compared to baseline (p=0.006) which was significantly higher than in the placebo treated group (T:-4.9%, P:-0.1% absolute change p=0.015).”

From study:1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

probability

Can suggest probability/likelihood

Assessment Explanation

The study is an RCT with control group, but blinding status unknown. Using 'likely associated' appropriately conveys the probabilistic nature of the causal inference.

Evidence from Studies

Supporting (1)

1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Randomized Controlled Trial

Human

Contradicting (0)

No contradicting evidence found

Source Study

1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Score: 63

DOI: 10.1093/ofid/ofad500.1334

Similar Assertions

People with HIV and fatty liver disease on INSTI drugs who took tesamorelin for a year likely saw their liver fat decrease by 31% compared to their starting point.

98%

For people with HIV and fatty liver disease on integrase inhibitors, taking tesamorelin for a year likely reduced liver fat by almost 5%, while the placebo group saw almost no change.

98%

For people with HIV and fatty liver disease on certain HIV drugs, taking tesamorelin for a year likely reduces belly fat by 8.3% while placebo makes it increase by 10.8%.

95%

For people with HIV and fatty liver on INSTI drugs, tesamorelin lowered liver fat by 4.9% compared to almost no change (0.1%) in the placebo group, which was a significant difference. This finding is from the abstract summary - full study details were not available

95%

For people with HIV and fatty liver disease who are taking integrase inhibitor drugs, taking tesamorelin for a year likely helped reduce belly fat, while those on a placebo saw their belly fat increase.

95%